265 related articles for article (PubMed ID: 27637910)
1. The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy.
Ramos JD; Casey MF; Bamias A; De Giorgi U; Bellmunt J; Harshman LC; Ladoire S; Wong YN; Alva AS; Rosenberg JE; Galsky MD; Yu EY;
Clin Appl Thromb Hemost; 2017 Oct; 23(7):755-760. PubMed ID: 27637910
[TBL] [Abstract][Full Text] [Related]
2. Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.
Ramos JD; Casey MF; Crabb SJ; Bamias A; Harshman LC; Wong YN; Bellmunt J; De Giorgi U; Ladoire S; Powles T; Pal SK; Niegisch G; Recine F; Alva A; Agarwal N; Necchi A; Vaishampayan UN; Rosenberg JE; Galsky MD; Yu EY;
Cancer Med; 2017 Jan; 6(1):186-194. PubMed ID: 28000388
[TBL] [Abstract][Full Text] [Related]
3. PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL).
Santi RM; Ceccarelli M; Catania G; Monagheddu C; Evangelista A; Bernocco E; Monaco F; Federico M; Vitolo U; Cortelazzo S; Cabras MG; Spina M; Baldini L; Boccomini C; Chiappella A; Bari A; Luminari S; Calabrese M; Levis A; Visco C; Contino L; Ciccone G; Ladetto M
Thromb Res; 2016 Apr; 140 Suppl 1():S177. PubMed ID: 27161692
[TBL] [Abstract][Full Text] [Related]
4. Performance of Khorana Risk Score for Prediction of Venous Thromboembolism in Patients With Hepatocellular Carcinoma.
Wang Y; Attar BM; Fuentes HE; Yu J; Zhang H; Tafur AJ
Clin Appl Thromb Hemost; 2018 Apr; 24(3):471-476. PubMed ID: 28288526
[TBL] [Abstract][Full Text] [Related]
5. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study.
Kruger S; Haas M; Burkl C; Goehring P; Kleespies A; Roeder F; Gallmeier E; Ormanns S; Westphalen CB; Heinemann V; Rank A; Boeck S
Thromb Res; 2017 Sep; 157():9-15. PubMed ID: 28675831
[TBL] [Abstract][Full Text] [Related]
6. [Predicting the Incidence of Venous Thromboembolism Using the Khorana Score: A Literature Review].
Nishimura A; Ikeda Y
Yakugaku Zasshi; 2021; 141(4):611-622. PubMed ID: 33790126
[TBL] [Abstract][Full Text] [Related]
7. Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer.
Parker A; Peterson E; Lee AYY; de Wit C; Carrier M; Polley G; Tien J; Wu C
J Thromb Haemost; 2018 Jul; 16(7):1321-1326. PubMed ID: 29733498
[TBL] [Abstract][Full Text] [Related]
8. Early venous thromboembolism at the beginning of palliative chemotherapy is a poor prognostic factor in patients with metastatic pancreatic cancer: a retrospective study.
Kim JS; Kang EJ; Kim DS; Choi YJ; Lee SY; Kim HJ; Seo HY; Kim JS
BMC Cancer; 2018 Dec; 18(1):1260. PubMed ID: 30558603
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK).
Kuderer NM; Poniewierski MS; Culakova E; Lyman GH; Khorana AA; Pabinger I; Agnelli G; Liebman HA; Vicaut E; Meyer G; Shepherd FA
Oncologist; 2018 Feb; 23(2):247-255. PubMed ID: 28951500
[TBL] [Abstract][Full Text] [Related]
10. Khorana Score: Νew Predictor of Early Mortality in Patients With Lung Adenocarcinoma.
Vathiotis I; Dimakakos EP; Boura P; Ntineri A; Charpidou A; Gerotziafas G; Syrigos K
Clin Appl Thromb Hemost; 2018 Nov; 24(8):1347-1351. PubMed ID: 29806470
[TBL] [Abstract][Full Text] [Related]
11. COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or immunotherapy, the CK-RAM study.
Abdel-Razeq H; Sharaf B; Al-Jaghbeer MJ; Abu-Fares H; Bater R; Shaer MA; Abu-Jaish H; Laban DA; Salamah O; Tamimi F; Ashouri K; Salameh T; Zughul R; Alhalaseh Y
J Thromb Thrombolysis; 2023 Oct; 56(3):447-453. PubMed ID: 37430158
[TBL] [Abstract][Full Text] [Related]
12. A modified Khorana score as a risk assessment tool for predicting venous thromboembolism in newly diagnosed advanced lung cancer.
Li S; Gao P; Qiu J; He X; Mao Y
J Thromb Thrombolysis; 2021 Oct; 52(3):898-903. PubMed ID: 33599857
[TBL] [Abstract][Full Text] [Related]
13. Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana Risk Score.
Rupa-Matysek J; Gil L; Kaźmierczak M; Barańska M; Komarnicki M
Med Oncol; 2017 Dec; 35(1):5. PubMed ID: 29209847
[TBL] [Abstract][Full Text] [Related]
14. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'.
Mandala M; Clerici M; Corradino I; Vitalini C; Colombini S; Torri V; De Pascale A; Marsoni S
Ann Oncol; 2012 Jun; 23(6):1416-21. PubMed ID: 22052988
[TBL] [Abstract][Full Text] [Related]
15. Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy.
Bamias A; Tzannis K; Dimitriadis I; Tsironis G; Papatheorodidi AM; Tsiara A; Fragkoulis C; Xirokosta A; Barbarousi D; Papadopoulos G; Zakopoulou R; Varkarakis I; Mitsogiannis I; Adamakis I; Alamanis C; Stravodimos K; Papatsoris AG; Dellis AE; Drivalos A; Ntoumas K; Matsouka H; Halvatsiotis P; Raptis A; Gerotziafas GT; Dimopoulos MA
Clin Genitourin Cancer; 2020 Aug; 18(4):e457-e472. PubMed ID: 32007440
[TBL] [Abstract][Full Text] [Related]
16. Identification of risk factors for venous thromboembolism and evaluation of Khorana venous thromboembolism risk assessment in Japanese lung cancer patients.
Hiraide M; Shiga T; Minowa Y; Nakano Y; Yoshioka H; Suzuki K; Yasuda C; Takahashi H; Hama T
J Cardiol; 2020 Jan; 75(1):110-114. PubMed ID: 31416782
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients.
Rupa-Matysek J; Lembicz M; Rogowska EK; Gil L; Komarnicki M; Batura-Gabryel H
Med Oncol; 2018 Apr; 35(5):63. PubMed ID: 29616356
[TBL] [Abstract][Full Text] [Related]
18. Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy.
Srikanthan A; Tran B; Beausoleil M; Jewett MA; Hamilton RJ; Sturgeon JF; O'Malley M; Anson-Cartwright L; Chung PW; Warde PR; Winquist E; Moore MJ; Amir E; Bedard PL
J Clin Oncol; 2015 Feb; 33(6):582-7. PubMed ID: 25605848
[TBL] [Abstract][Full Text] [Related]
19. The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis.
van Es N; Ventresca M; Di Nisio M; Zhou Q; Noble S; Crowther M; Briel M; Garcia D; Lyman GH; Macbeth F; Griffiths G; Iorio A; Mbuagbaw L; Neumann I; Brozek J; Guyatt G; Streiff MB; Baldeh T; Florez ID; Gurunlu Alma O; Agnelli G; Ageno W; Marcucci M; Bozas G; Zulian G; Maraveyas A; Lebeau B; Lecumberri R; Sideras K; Loprinzi C; McBane R; Pelzer U; Riess H; Solh Z; Perry J; Kahale LA; Bossuyt PM; Klerk C; Büller HR; Akl EA; Schünemann HJ;
J Thromb Haemost; 2020 Aug; 18(8):1940-1951. PubMed ID: 32336010
[TBL] [Abstract][Full Text] [Related]
20. Influence of type 2 diabetes mellitus on Khorana venous thromboembolism risk in colorectal cancer patients.
Wang R; Liu R; Zhao L; Xu D; Hu L
Rev Esp Enferm Dig; 2017 Jul; 109(7):503-509. PubMed ID: 28593781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
